SCHEMBL3845186

SCHEMBL3845186

COC(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(C(N)=O)cc1)c1ccccc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 5/20 0.43
CTDSP1 Q9GZU7 1/20 0.43
PLAU P00749 1/20 0.43
PLAT P00750 1/20 0.43
BACE1 P56817 2/20 0.43
SMN1; SMN2 Q16637 3/20 0.42
POLB P06746 3/20 0.42
L3MBTL1 Q9Y468 3/20 0.42
PTPN1 P18031 1/20 0.42
TP53 P04637 1/20 0.42
THRB P10828 1/20 0.42
BLM P54132 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
MEN1 O00255 3/20 0.41
MAPT P10636 2/20 0.41
RAB9A P51151 2/20 0.40
CASP1 P29466 1/20 0.40
ALOX5 P09917 1/20 0.40
ALDH1A1 P00352 3/20 0.39
LMNA P02545 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2120036 0.93 RAB9A (0.46) KMT2ACTDSP1BACE1SMN1; SMN2POLB
SCHEMBL479876 0.93 RAB9A (0.46) KMT2ACTDSP1BACE1SMN1; SMN2POLB
SCHEMBL480667 0.93 KMT2A (0.44) KMT2ACTDSP1BACE1SMN1; SMN2POLB
SCHEMBL480665 0.93 KMT2A (0.44) KMT2ACTDSP1BACE1SMN1; SMN2POLB
SCHEMBL2569239 0.92 SMN1; SMN2 (0.46) KMT2ACTDSP1BACE1SMN1; SMN2POLB
SCHEMBL20807346 0.92 KMT2A (0.46) KMT2ACTDSP1BACE1SMN1; SMN2POLB
SCHEMBL2569238 0.92 SMN1; SMN2 (0.46) KMT2ACTDSP1BACE1SMN1; SMN2POLB
SCHEMBL480759 0.92 KMT2A (0.43) KMT2ACTDSP1PLAUBACE1SMN1; SMN2
SCHEMBL480757 0.92 KMT2A (0.43) KMT2ACTDSP1PLAUBACE1SMN1; SMN2
SCHEMBL16752527 0.91 BACE1 (0.54) KMT2ACTDSP1BACE1SMN1; SMN2POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1830842-B1 MEDICAMENTS FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES BOEHRINGER INGELHEIM INT (DE) 2009-04-22 EP disclosed
US-20090048267-A1 MEDICAMENTS FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-02-19 US disclosed
US-20060154939-A1 Medicaments for the Treatment or Prevention of Fibrotic Diseases BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2006-07-13 US disclosed
US-6858641-B2 Substituted indolinones BOEHRINGER INGELHEIM PHARMA KG (DE) 2005-02-22 US disclosed
US-20030092756-A1 Substituted indolinones BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2003-05-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030092756-A1 Substituted indolinones CDK1, CDK2, CDKL1 KMT2A 2176/4885CTDSP1 531/4885PLAU 4028/4885
US-20060154939-A1 Medicaments for the Treatment or Prevention of Fibrotic Diseases MMP1, COL1A1, FOXM1 KMT2A 4592/4885CTDSP1 3824/4885PLAU 1500/4885
US-20090048267-A1 MEDICAMENTS FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES COL1A1, MMP1, FOXM1 KMT2A 4673/4885CTDSP1 3758/4885PLAU 1713/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.